Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF). Its novel therapeutic principle is aimed at addressing a pathophysiological core element of acute heart failure – renal venous congestion and its deleterious effects on renal and cardiac function.
The experimental animal data of the device are compelling and in line with a vast and growing body of clinical and experimental evidence supporting the therapeutic concept. The company is currently conducting a European multicenter clinical trial on the path to obtaining the CE Mark.
Heart failure is a pandemic affecting tens of millions of people worldwide, among them 15 million Europeans and more than 6.5 million Americans. The market for heart failure devices is expected to grow to close to $15 billion by 2022. ADHF is the leading cause of hospitalization in the EU and the US, placing a heavy burden on patients and society. The annual costs of hospitalizations currently amount to $26 billion in the US alone, and are projected to more than double over the next 15 years.